Vom 3. bis 9. November 2021 fassen unsere Schweizer Rheumaexperten für Sie die praxisrelevantesten Abstracts des ACR-Kongresses zusammen und kommentieren diese.
Rheumatoid Arthritis
Abstracts
- 06.11.2021 | 0116 | Covid-19 side effects
- 06.11.2021 | 0117 | Flares after zoster vaccination
- 06.11.2021 | 0455 | Abatacept and subclinical arthritis
- 08.11.2021 | 1444 | MTX and nausea/alopecia: predictors
- 09.11.2021 | 1942 | DMARDs and skin cancer
- 09.11.2021 | 1941 & 0958 | Safety of Tofacitinib in rheumatoid arthritis (RA)
Psoriatic Arthritis
Abstracts
- 06.11.2021 | 0453 | Risankizumab: A new kid on the ground
- 08.11.2021 | 1323 | Uveitis: A relevant non-musculoskeletal manifestation of PsA
- 09.11.2021 | L12 | MTX in PsA: Necessary when treated with IL12/Il23 inhibitors?
- 09.11.2021 | 1722 | PsA: Pregnant women have an increased risk of pre-eclampsia
- 09.11.2021 | 1798 | Which psoriasis patients develop psoriatic arthritis during follow-up?
Spondyloarthritis
Abstracts
- 06.11.2021 | 0451 | TNFi and radiographic progression in SpA
- 06.11.2021 | 0489 | SpA: a new selective MK2 inhibitor
- 06.11.2021 | 0380 | SpA: sick leave and predictors
- 08.11.2021 | 1311 | Psoriasis of the skin: onset at any timepoint
- 09.11.2021 | 1922 | SpA: early diagnosis
- 09.11.2021 | 1945 | PsA with axial involvement: Upadacitinib
Vasculitis
Abstracts
- 06.11.2021 | 0430 | ILD in ANCA vasculitis
- 06.11.2021 | 0432 | EGPA: Anti-IL5 treatment
- 07.11.2021 | 0952 | Covid-19 infection in vasculitis
- 07.11.2021 | 0954 | ANCA vasculitis: RTX vs. CYC
- 08.11.2021 | 1412 | GCA: Tocilizumab and visual involvement
- 09.11.2021 | L21 | EGPA: RTX vs. conventional therapy
Connective Tissue Diseases
Abstracts
- 06.11.2021 | 0443 | Belimumab for myositis
- 06.11.2021 | 0496 | Rituximab for systemic sclerosis
- 07.11.2021 | 0959 | Hydroxychloroquine and SLE
- 07.11.2021 | 0957 | Vitamin D and fatty acid supplementation for prevention of disease
- 07.11.2021 | 0986 | Ianalumab and Sjögren’s syndrome
- 08.11.2021 | 1425 | Voclosporin for lupus nephritis
Additional Topics (incl. Covid19)
Abstracts
- 06.11.2021 | 0102 | Outcome of SARS-CoV-2 infection in rheumatic disease
- 06.11.2021 | 0108 | SARS-CoV-2 vaccine in rheumatic disease
- 06.11.2021 | 0149 | Impact of weight training
- 06.11.2021 | 0447 | Anabolic bone effects: new drug
- 07.11.2021 | 0729 | Lorecivivint for knee OA
- 08.11.2021 | 1040 | Gammopathy in autoimmune disease
- 09.11.2021 | 1585 | Treatment of adhesive capsulitis